Prof. Thomas Lynch
Dr. Thomas Lynch joined Bristol-Myers Squibb in March 2017 as Chief Scientific Officer to lead the Research & Development organization bringing broad leadership experience, significant experience in drug development and a deep understanding of the patient perspective as a treating oncologist. He previously served as a Director on Bristol-Myers Squibb’s Board from 2013-2017.
Tom has more than 30 years of medical, management and leadership experience, including more than 23 years at Massachusetts General Hospital (MGH). He served as Chairman and Chief Executive Officer of Massachusetts General Physicians Organization and as a member of the MGH Board from 2015 to 2017.
Before his roles as Chairman and CEO at MGH, Tom served as the Director of Yale Cancer Center and was the Richard and Jonathan Sackler Professor of Internal Medicine at the Yale School of Medicine from 2009 to 2015. He also served as the Physician in Chief of Smilow Cancer Hospital, Yale New Haven from 2009 to 2015. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. While at MGH in 2004, Tom was part of the team credited with the significant discovery that certain genetic mutations in lung cancer patients caused therapies to work for some individuals and not for others.
Tom is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.
Proudly supported by BMS.
Prof. Tony Mok
Professor Tony Mok
BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO
Professor Tony S.K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.
Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at the Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. These projects address various aspects on management of EGFR mutation positive lung cancer, and basically have defined the current practice. He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by Professor Mok, have defined precision medicine for lung cancer. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO. He also contributes to the development of clinical research infra-structure in China and Asia. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.
Professor Mok has contributed to over 220 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. He is the Past President and Current Treasurer of the International Association for the Study of Lung Cancer (IASLC). He serves on ASCO Board of Directors from 2018 to 2022. He is active in international education activity and has made significant contribution to AACR, ASCO, CSCO and ESMO. His work was recognized by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul Bunn Jr Scientific Award in 2017 and National Science and Technology Progress Award in 2017. His recent article in the New England Journal of Medicine has been selected as one of the most “Notable Articles in 2017.”
Proudly supported by Roche Oncology.
Assoc. Prof Justin Gainor
Justin Gainor, MD, a thoracic oncologist at the Mass General Cancer Center, conducts intensive research on developing novel targeted therapies for patients with genetically-defined forms of lung cancer and designs clinical trials to evaluate these complex, life-saving treatments.
Concurrently, he is delving into the role of the immune system as a means to combat cancer. In recent years, immunotherapies targeting the PD-1 protein have reshaped the management of a number of malignancies. Dr. Gainor is now spearheading Mass General’s clinical trials assessing similar strategies in lung and esophageal cancer. Lastly, he is exploring the intersection of targeted therapies and immunotherapy, both on a clinical and translational level.
Proudly supported by Pfizer Oncology.
Prof. Hisao Asamura
Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan
Born in Osaka in 1957. Graduated from Keio University School of Medicine in 1983. Internship at the Keio University Hospital and affiliated hospitals (1983-85). Residency in general surgery and Clinical fellow in thoracic surgery at the National Cancer Center Hospital (1986-91). Attending surgeon (Thoracic surgery, 1992-1998), Chief of Thoracic Surgery (1992-2014), and Deputy Director-Hospital (2012-2014) at the National Cancer Center Hospital, Tokyo. Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine (2014-present). Visiting Professor at the Kyorin University in Tokyo (2007-2013) and at the Seoul National University in Seoul, Korea (1999-preseent). Doctor of Medical Science degree from Keio University in 1997.
Chair of Staging Committee (IASLC). Executive Board Director and Chair of the Committee for General Rules of Pathological and Clinical Record for Lung Cancer (Japan Lung Cancer Society). Chair, TNM Committee (Japan UICC Committee) and member of TNM Prognostic Factors Core Group, UICC, Geneva. A Congress President for 58th World Conference on Lung Cancer in Yokohama 2017 by IASLC.
Wittekind C, Asamura H, Sobin LH. TNM Atlas. Wiley Blackwell, 2014.
Asamura H. Asamura’s Operative Thoracic Surgery. Kanehara Co, 2011
Dr José Belderbos
Dr. José Belderbos received her medical degree at the Rijk Universiteit of Utrecht, the Netherlands, in 1988, and became a radiation oncologist at the General Hospital Middelheim, Antwerp, Belgium. She has been a staff member at the Department of Radiotherapy at the Netherlands Cancer Institute (NKI)/ Antoni van Leeuwenhoek since 1994. In March 2007 she obtained her PhD from the University of Amsterdam with the thesis ‘Radiotherapy in lung cancer: a moving field’ (promoter Prof. dr. G.M. Bartelink and Co-promoter Dr. J.V. Lebesque).
Dr Belderbos specializes in lung cancer and individualized dose escalation in non-small cell lung cancer (NSCLC) using intensity modulated radiotherapy and image guided radiotherapy with tight treatment margins.
De Belderbos is currently chairman of the multidisciplinary Dutch Lung Radiotherapy Audit (DLRA). Since 2011 she is also chairman of the Dutch Platform for Radiation Oncologists that specialize in treating lung cancer. Furthermore, she is a reviewer for several international journals and scientific committees.
From 1999 until 2007 she chaired the Regional Working Group on Lung Tumors of the Netherlands Comprehensive Cancer Organization. She was also a board member of the Dutch Lung Cancer Research Group.
José Belderbos was a faculty member for ESTRO, ASTRO, ICTR and ESMO as well as a Scientific Committee Member of IASLC, ESTRO and ASTRO.
She is a member of the Dutch Guideline Committee for lung cancer.
Dr Belderbos coordinated work packages in an European Union project: Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE).
She has supervised many PhD students and is the study coordinator of several phase I-III trials. Her research areas focus on optimization of stereotactic image guided radiotherapy for lung cancer, individualized radiation-dose escalation using pre-treatment FDG-PET scan information, combining targeted agents with radiotherapy, cost-effectiveness, immune therapy and hippocampus avoidance prophylactic cranial irradiation.
Dr. Belderbos has received grants for several project from the Dutch Cancer Society (KWF) and the Dutch Society for Medical Specialists (SKMS).
Dr. Belderbos has published over 150 peer-reviewed papers and chapters in several scientific books.
Assoc. Prof Marianne Davies
Assistant Professor Marianne J. Davies, returned to Yale University with multiple years of graduate teaching experience at YSN, and has been involved at Yale-New Haven Hospital’s Cancer Center since 1983. In the past Davies has worked as an advanced oncology certified nurse. She is currently an acute care nurse practitioner, advanced oncology certified nurse practitioner and clinical nurse specialist in adult health.
She began her nursing education at Russell Sage College in 1983. She continued her education in New Haven, Conn., and received both her Masters and Post Master’s Certificate at YSN. Davies then pursued a Doctorate of Nursing Practice at the MGH Institute of Health Profession in Boston, Mass.
In addition to teaching, Davies has received various awards and honors. She is the recipient of Cogswell Award, Outstanding Student Leadership and Community Involvement, Yale-New Haven Hospital Medical Staff Patient Experience Recognition, the Ruth McCorkle Oncology Advanced Practice Provider: Yale Cancer Center and Nightingale Award for Excellence in Nursing. Davies also belongs to Sigma Theta Tau, the National Honor Society of Nursing, the Connecticut Nurse Practitioner Association, the Oncology Nursing Society and the International Association for the Study of Lung Cancer.